Mexico Neurology Clinical Trials Market Report 2022 to 2030

Mexico Neurology Clinical Trials Market Analysis

$ 3999

The Mexico Neurology Clinical Trials market is projected to grow from $78.5 Mn in 2022 to $122.7 Mn by 2030, registering a CAGR of 5.75% during the forecast period of 2022 - 2030. The market will be driven by the rising frequency of neurological illnesses and increased investments in R&D by pharmaceutical companies. The market is segmented by phase, by study design & by indication. Some of the major players include Pfizer Inc., Novartis AG & Laboratorios Silanes.

ID: IN10MXCT005 CATEGORY: Clinical Trials GEOGRAPHY: Mexico AUTHOR: Vidhi Upadhyay

Buy Now

Mexico Neurology Clinical Trials Market Executive Summary

The Mexico Neurology Clinical Trials market is projected to grow from $78.5 Mn in 2022 to $122.7 Mn by 2030, registering a CAGR of 5.75% during the forecast period of 2022 - 2030. In 2022, the population aged 65 years and above in Mexico was 8.3 %. The worldwide predicted prevalence of dementia in the Mexican population was 7.8% for Alzheimer's disease, 4.3% for vascular dementia, and 2.1% for mixed dementia. The prevalence of dementia was greater in women than in males (15.3% vs 12.5%, respectively).

Neurology clinical trials in Mexico potentially take place at a range of hospitals and research institutions around the country. This research might focus on a wide range of neurological diseases, such as stroke, epilepsy, multiple sclerosis, Alzheimer's disease, and Parkinson's disease. There are many hospitals and research centres in Mexico that conduct neurological clinical trials such as the National Institute of Neurology and Neurosurgery, Hospital General de Mexico, Hospital Angeles & Hospital Universitario de Monterrey. In February 2020, Zhittya Genesis Medical, Inc. reported it had gained formal regulatory permission from COFEPRIS, Mexico's regulatory agency, to test its innovative biological drug in Parkinson's disease patients. The Phase 1 clinical trial will be undertaken in the Zambrano Hospital in Monterrey, Mexico, a cutting-edge medical facility.

The neurology clinical trials market in Mexico is likely to expand further in the coming years, due to factors such as increased R&D investment, the rising frequency of neurological illnesses, and the country's favourable regulatory environment.

Mexico Neurology Clinical Trials Market

Market Dynamics

Market Growth Drivers

Mexico has a big and diversified patient population, making it an appealing site for clinical trials seeking a broad patient group. Because of this variety, a more realistic portrayal of the worldwide patient population is possible. It also has a well-developed clinical trial regulatory system that is in line with international norms. The Federal Commission for Protection Against Sanitary Risk (COFEPRIS) monitors clinical trials in the nation and guarantees that they are done ethically and transparently. Mexico has an expanding research infrastructure, comprising research institutes and hospitals with cutting-edge facilities and knowledgeable employees. This infrastructure creates a favourable environment for clinical trials. Moreover, it is often seen as a cost-effective site for clinical trials, since it has lower trial expenditures than many other nations.

Market Restraints

Although Mexico has some well-established research institutes and hospitals in big cities, infrastructure in rural regions may be lacking. This may restrict patients in remote locations' access to clinical trials. Clinical trial funding in Mexico may be restricted, particularly for those done by local researchers. This might restrict the number of trials that can take place in the nation. Spanish is Mexico's official language; English is commonly used in the clinical research sector. Nonetheless, some patients may have the inadequate ability in either language, making participation in clinical studies with complex informed consent procedures challenging.

Competitive Landscape

Key Players

Pfizer Inc.
Novartis AG
Sanofi
Zhittya Genesis Medicine
Janssen
Bayer AG
Grupo Ferrer
Laboratorios Silanes (MEX)

Notable Insights

February 2020, Zhittya Genesis Medical, Inc. reported it had gained formal regulatory permission from COFEPRIS, Mexico's regulatory agency, to test its innovative biological drug in Parkinson's disease patients. The Phase 1 clinical trial will be undertaken in the Zambrano Hospital in Monterrey, Mexico, a cutting-edge medical facility.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Clinical Trials Regulation in Country
1.6 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Market Size (With Excel and Methodology)
2.2 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation

6. Methodology and Scope

Neurology Clinical Trials Market Segmentation

By Phase (Revenue, USD Billion):

Phase I
Phase II
Phase III
Phase IV

By Study Design Outlook (Revenue, USD Billion):

Epilepsy
Parkinson's Disease (PD)
Huntington's Disease
Stroke
Traumatic Brain Injury (TBI)
Amyotrophic Lateral Sclerosis (ALS)
Muscle regeneration
Others

By Indication Outlook (Revenue, USD Billion):

Interventional
Observational
Expanded Access

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.